Lupus anticoagulant

ICD-9 | 289.81
DiseasesDB | 775
MeSH | D016682

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

WikiDoc Resources for Lupus anticoagulant

Articles

Most recent articles on Lupus anticoagulant

Most cited articles on Lupus anticoagulant

Review articles on Lupus anticoagulant

Articles on Lupus anticoagulant in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lupus anticoagulant

Images of Lupus anticoagulant

Photos of Lupus anticoagulant

Podcasts & MP3s on Lupus anticoagulant

Videos on Lupus anticoagulant

Evidence Based Medicine

Cochrane Collaboration on Lupus anticoagulant

Bandolier on Lupus anticoagulant

TRIP on Lupus anticoagulant

Clinical Trials

Ongoing Trials on Lupus anticoagulant at Clinical Trials.gov

Trial results on Lupus anticoagulant

Clinical Trials on Lupus anticoagulant at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lupus anticoagulant

NICE Guidance on Lupus anticoagulant

NHS PRODIGY Guidance

FDA on Lupus anticoagulant

CDC on Lupus anticoagulant

Books

Books on Lupus anticoagulant

News

Lupus anticoagulant in the news

Be alerted to news on Lupus anticoagulant

News trends on Lupus anticoagulant

Commentary

Blogs on Lupus anticoagulant

Definitions

Definitions of Lupus anticoagulant

Patient Resources / Community

Patient resources on Lupus anticoagulant

Discussion groups on Lupus anticoagulant

Patient Handouts on Lupus anticoagulant

Directions to Hospitals Treating Lupus anticoagulant

Risk calculators and risk factors for Lupus anticoagulant

Healthcare Provider Resources

Symptoms of Lupus anticoagulant

Causes & Risk Factors for Lupus anticoagulant

Diagnostic studies for Lupus anticoagulant

Treatment of Lupus anticoagulant

Continuing Medical Education (CME)

CME Programs on Lupus anticoagulant

International

Lupus anticoagulant en Espanol

Lupus anticoagulant en Francais

Business

Lupus anticoagulant in the Marketplace

Patents on Lupus anticoagulant

Experimental / Informatics

List of terms related to Lupus anticoagulant

## Contents

* 1 Overview
* 2 Workup
* 3 Treatment
* 4 Monitoring the INR in a Patient with Lupus Anticoagulant
* 5 References
* 6 External links

## Overview

[edit | edit source]

Lupus anticoagulant (also known as lupus antibody, LA, or lupus inhibitors) is a medical phenomenon where autoantibodies bind to phospholipids and proteins associated with the cell membrane. Since interactions between the cell membrane and clotting factors are necessary for proper functioning of the coagulation cascade, the lupus anticoagulant can interfere with blood clotting as well as in-vitro tests of clotting function. Paradoxically, lupus anticoagulants are also risk factors for thrombosis.

The name "lupus anticoagulant" is a misnomer. Most patients with a lupus anticoagulant do not actually have lupus erythematosus, and only a small proportion will proceed to develop this disease (which causes joint pains, skin problems and renal failure, amongst other complications). Patients with lupus erythematosus are more likely to develop a lupus anticoagulant than the general population.

Conceptually, lupus anticoagulants overlap with the antiphospholipid antibody syndrome. Lupus anticoagulants can be understood as the tendency of antiphospholipid antibodies to prolong the clotting times, especially in phospholipid rich clotting testing such as the dilute Russell's viper venom time.

Often, the lupus anticoagulant is diagnosed on asymptomatic patients by a routine blood testing prior to surgery. Patients with a lupus anticoagulant are prone to thrombosis, excess bleeding, and habitual abortion (repeated miscarriages).

## Workup

[edit | edit source]

The presence of prolonged clotting times on a routine blood test often triggers functional testing of the blood clotting function, as well as serological testing to identify common autoantibodies such as antiphospholipid antibodies. These antibodies tend to delay in-vitro coagulation in phospholipid-dependent laboratory tests such as the partial thromboplastin time.

The initial workup of a prolonged PTT is a mixing test whereby the patient's blood is mixed with normal blood and the clotting is re-assessed. If a clotting inhibitor such as a lupus anticoagulant is present, the inhibitor will interact with the normal blood and the clotting time will remain abnormal. However, if the clotting time of the mixed blood corrects towards normal, the diagnosis of an inhibitor such as the lupus anticoagulant is excluded; the diagnosis is a deficient clotting factor that is replenished by the normal blood.

If the mixing test indicates an inhibitor, diagnosis of a lupus anticoagulant is then confirmed with phospholipid-sensitive functional clotting testing, such as the dilute Russell's viper venom time, or the Kaolin clotting time. Excess phospholipid will eventually correct the prolongation of these prolonged clotting tests (conceptually known as "phospholipid neutralization" in the clinical coagulation laboratory), confirming the diagnosis of a lupus anticoagulant.

## Treatment

[edit | edit source]

Treatment for a lupus anticoagulant is usually undertaken in the context of documented thrombosis, such as extremity phlebitis or dural sinus vein thrombosis. Patients with a well-documented (i.e., present at least twice) lupus anticoagulant and a history of thrombosis should be considered candidates for indefinite treatment with anticoagulants. Patients with no history of thrombosis and a lupus anticoagulant should probably be observed. Current evidence suggests that the risk of recurrent thrombosis in patients with an antiphospholipid antibody is enhanced whether that antibody is measured on serological testing or functional testing. The Sapporo criteria specify that both serological and functional tests must be positive to diagnose the antiphospholipid antibody syndrome . [1].

Miscarriages may be more prevalent in patients with a lupus anticoagulant. These can be prevented with the administration of low molecular weight heparins (LMWHs), and thrombosis is treated with anticoagulants (LMWHs and warfarin).[2]

## Monitoring the INR in a Patient with Lupus Anticoagulant

[edit | edit source]

Some lupus anticoagulants interfere with the INR determination. They may lead to an elevated INR even if a patient is not on warfarin (=coumadin®)[3]

## References

[edit | edit source]

1. ↑ Viard JP, Amoura Z, Bach JF (1991). "[Anti-beta 2 glycoprotein I antibodies in systemic lupus erythematosus: a marker of thrombosis associated with a circulating anticoagulant]". C. R. Acad. Sci. III, Sci. Vie (in French). 313 (13): 607–12. PMID 1782567.CS1 maint: Multiple names: authors list (link) CS1 maint: Unrecognized language (link)
2. ↑ Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H (2006). "A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages". Fertil Steril. 86 (2): 362–6. PMID 16769056.CS1 maint: Multiple names: authors list (link)
3. ↑ Ann Intern Med 1997;127:177-185: "Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants"

## External links

[edit | edit source]

* Information on lupus anticoagulant from the American Association for Clinical Chemistry
* Lupus+anticoagulant at the US National Library of Medicine Medical Subject Headings (MeSH)

Template:Autoantibodies

Template:Jb1

Template:WikiDoc Sources